• Explore /
  • Poster
  • / Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

Abstract Video & Slides Poster

Authors

Larry Anderson, Jr, Jr

Larry D. Anderson, Jr

The University of Texas Southwestern Medical Center, Dallas, TX

Larry D. Anderson, Jr , Nikhil C. Munshi , Nina Shah , Sundar Jagannath , Jesus G. Berdeja , Sagar Lonial , Noopur S. Raje , David Samuel DiCapua Siegel , Yi Lin , Albert Oriol , Philippe Moreau , Ibrahim Yakoub-Agha , Michel Delforge , Fabio Petrocca , Payal Patel , Liping Huang , Timothy B. Campbell , Kristen Hege , Jesús F. San-Miguel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders

Clinical Trial Registration Number

NCT03361748

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8016)

DOI

10.1200/JCO.2021.39.15_suppl.8016

Abstract #

8016

Abstract Disclosures

Similar Posters

First Author: Dan T. Vogl

First Author: Ian W. Flinn

First Author: Andrew J Yee

First Author: Adriana C. Rossi